ECOZA (econazole nitrate) by PharmaIN is 12. Approved for interdigital tinea pedis caused by trichophyton rubrum, trichophyton mentagrophytes, epidermophyton floccosum in patients 12 years of age and 1 more indications. First approved in 2013.
Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
ECOZA is a topical foam formulation of econazole nitrate, an azole antifungal that inhibits fungal cytochrome P-450-mediated lanosterol demethylase, disrupting ergosterol synthesis in the fungal cell wall. It is indicated for interdigital tinea pedis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum in patients 12 years of age and older. The drug is applied topically once daily with minimal systemic absorption.
ECOZA is in peak commercial lifecycle with moderate competitive pressure (8/10), indicating stable market position but requiring active promotional and field support to defend share against multiple alternatives.
12.1 Mechanism of Action Ecoza topical foam is an azole antifungal [ see ] . 12.2 Pharmacodynamics The pharmacodynamics of Ecoza topical foam, 1% have not been established . 12.3 Pharmacokinetics The systemic absorption of Ecoza topical foam, 1% following topical application was studied in one…
Worked on ECOZA at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Therapeutic Equivalence and Safety of Two Econazole Nitrate Cream, 1% Products in Tinea Pedis
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~5 years — strategic planning for patent cliff underway
ECOZA offers career opportunities primarily in commercial and field-based roles during its peak lifecycle phase, with emphasis on defending market share against multiple competitors and managing the transition toward LOE. Working on this product provides exposure to dermatology commercial execution, competitive strategy, and pharmaceutical lifecycle management in a crowded topical antifungal market.